Monoclonal anti-acid-labile subunit oligopeptide antibodies and their use in a two-site immunoassay for ALS measurement in humans
Introduction
The acid-labile subunit (ALS), a 578 amino acid protein with a calculated molecular weight of 63.3 kDa, forms a 150-kDa ternary complex in conjunction with insulin-like growth factor binding protein (IGFBP3) (and to a lesser extent IGFBP5; Twigg and Baxter, 1998) and insulin-like growth factor I or II (IGF-I or IGF-II) (Baxter, 1990). To form this ternary complex, IGFBP3 and IGF usually first form a binary complex, to which ALS then associates. Recently, some evidences suggest that there might also be complex formation of ALS and IGFBP3 without IGF (Lee et al., 1997).
In serum, the ALS molecule is present as an 82–88-kDa glycoprotein showing a double band on western immunoblot (Baxter et al., 1989). In contrast to the IGF binding protein 3, the synthesis of ALS, which is regulated directly by growth hormone (GH), occurs in the hepatocytes and in the epithelium of the proximal tubule of the renal cortex (Chin et al., 1994).
ALS contains 18–20 leucine-rich repeats of 24 amino acids (Leong et al., 1992) that are found in other human proteins as well, and are thought to be important in protein–protein interaction. For this reason, monoclonal antibodies (mAbs) were generated against the specific amino(N)-terminal and carboxyl(C)-terminal sequences of ALS, which contain no leucine-rich repeats and represent the unique sequences of ALS (Leong et al., 1992).
Under acidic conditions, ALS dissociates from IGF and IGFBP3, and neutralization is unable to restore the ternary complex (Hintz and Liu, 1977). Although binary complex formation between IGFs and IGFBP3 persists, ALS loses almost all binding activities below a pH of 4.5 (Holman and Baxter, 1996). This characteristic of ALS was used when pretreating the sera with an acidic glycine-buffer with the intention of “unfolding” the ALS protein so that it could be recognized by the mAbs that had been generated against the synthetic terminal oligopeptide sequences of ALS.
As ALS is produced mainly in hepatocytes under the direct control of GH, it represents a potential marker of GH secretory status and/or GH effects. The goal of this work was to establish a specific immunoassay based on mAb for quantitative ALS determination in biological samples.
Section snippets
Generation and purification of monoclonal antibodies
The synthetic human ALS oligopeptide sequences of the N-terminal (aa: 1–34) and C-terminal (aa: 551–578) of the ALS molecule were prepared by solid phase synthesis, isolated from the IGF–IGFBP3 column by acidification, and coupled to ovalbumin in a ratio of 2.3–3:1 by the glutardialdehyde method (Avrameas et al., 1978). The resulting immunogen was used to immunize BALB-C mice. The spleen cells were fused with NS0 myeloma cells following the hybridoma technique of Köhler and Milstein (1975) and
Anti-C- and N-terminal monoclonal antibodies of ALS
After the first screening, nine anti-N-terminal ALS mAbs and 10 anti-C-terminal ALS mAbs were identified. A clone was considered to be positive when its supernatant gave a signal in the assay that was more than 10-fold greater than the positive control (diluted blood from the immunized mouse collected at the time of fusion). The immunoglobulin subclasses of the anti-N-terminal ALS mAbs are mainly of subclass G2b, whereas the anti-C-terminal ALS mAbs belong, predominantly, to the subclass G1.
ALS levels in hGH-deficient patients
ALS levels were measured in 12 hGH-deficient individuals before and after 1 year of hGH replacement therapy. Prior to therapy, the ALS levels ranged from 36 to 986 mU/ml. The smallest increase in ALS level after therapy was 241 mU/ml and the maximal increase was 1340 mU/ml (Fig. 6). After 1 year of hGH replacement therapy, the mean ALS concentration had increased from 514 (±347) to 1223 (±458) mU/ml (p<0.0006).
Correlation between the changes in ALS levels with changes in IGF-I and IGFBP3 levels
Conclusion/discussion
The monoclonal N-terminal 5C9 and C-terminal 7H3 antibodies (Ab) against ALS represent an antibody pair that enables the measurement of ALS in human serum in a specific and reliable manner. The method of Ab selection prevents cross-reactions of the mAb with other known serum proteins. By covalently linking the N-terminal and C-terminal ALS oligopeptides to the surface of the microtiter plates in an orientation allowing binding of potential monoclonal antibodies, it was assured that the Abs
Acknowledgements
The authors would like to acknowledge the support of this work by Mr. Gopal Savjani, DSL, Webster, TX.
References (15)
- et al.
High molecular weight insulin-like growth factor binding protein complex
Journal of Biological Chemistry
(1989) - et al.
Coupling of enzymes to antibodies antigens
Scandinavian Journal of Immunology
(1978) Circulating levels and molecular distribution of the acid-labile subunit of the high molecular weight insulin-like growth factor binding protein complex
Journal of Clinical Endocrinology and Metabolism
(1990)- et al.
Cellular localization and regulation of gene expression for components of the insulin-like growth factor ternary binding protein complex
Endocrinology
(1994) - et al.
Demonstration of specific protein binding sites for somatomedin
Journal of Clinical Endocrinology and Metabolism
(1977) - et al.
Insulin-like growth factor binding protein-3: factors affecting binary and ternary complex formation
Growth Regulation
(1996) - et al.
The acid-labile subunit of human ternary insulin-like growth factor binding protein complex in serum: hepatosplanchnic release, diurnal variation, circulation concentrations in healthy subjects, and diagnostic use in patients with growth hormone deficiency
Journal of Clinical Endocrinology and Metabolism
(1998)
Cited by (18)
Resistance training-induced improvement in physical function is not associated to changes in endocrine somatotropic activity in prefrail older adults
2022, Archives of Gerontology and GeriatricsCitation Excerpt :Extensive validation data as well as age-adjusted reference intervals for the assays used have been published elsewhere (Bidlingmaier et al., 2014). Serum ALS concentrations were measured in duplicate by a sandwich-type immunofluorometric assay using monoclonal antibodies directed against specific N- and C-terminal oligopeptides (Stadler et al., 2001). A serum pool of healthy male volunteers was used for calibration.
Systemic response of the GH/IGF-I axis in timely versus delayed fracture healing
2008, Growth Hormone and IGF ResearchCitation Excerpt :For the IGFBP-3 assay, within- and between-assay variability for the IGFBP-3 assay was <2.8% and <5.9%, respectively. Serum ALS levels (mU/l) were measured in duplicate by sandwich immunometric assay using monoclonal antibodies directed against specific N- and C-terminal oligopeptides [16,17]. To optimize immunorecognition, samples were pre-treated with 3 M urea and 0.05% SDS.
Quantitative ontogeny of murine insulin-like growth factor (IGF)-I, IGF-binding protein-3 and the IGF-related acid-labile subunit
2008, Growth Hormone and IGF ResearchThe diagnosis of partial growth hormone deficiency in adults with a putative insult to the hypothalamo-pituitary axis
2007, Journal of Clinical Endocrinology and MetabolismComparative pharmacokinetics and pharmacodynamics of a new sustained-release growth hormone (GH), LB03002, versus daily GH in adults with GH deficiency
2006, Journal of Clinical Endocrinology and Metabolism